Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

Inclusion Criteria:

- ≥ 18 years old

- DOAC administered for a minimum of 7 days

Exclusion Criteria:

- Genetic Bleeding disorders. Known or subsequently discovered inherited defects of
coagulation (e.g. hemophilia or Von Willebrand disease)

- Not known when last two DOAC doses were administered prior to blood draw

- DOAC first administered (or resumed after temporary cessation) less than 7 days prior
to blood draw

- DOAC dosage outside of manufacturer's recommended range (e.g. study subject with renal
impairment and supratherapeutic dose)

- Heparin or LMWH administered within 7 days prior to blood draw

- On any medications known to affect coagulation status and listed below

- Bruising, wounds or scarring in the area of venipuncture

List of medications known to affect coagulation status

1. Vitamin K Antagonists [VKAs] Warfarin Phenprocoumon Acenocoumarol Tecarfarin
[ATI-5923] Phenindione Anisindione Elinogrel Vorapaxar Atopaxar

2. Heparin and Heparins Unfractionated Heparin [UFH] LMWH Fondaparinux Idraparinux
Danaparoid

3. Vasopressin Analogues DDAVP

4. Direct Thrombin [IIa] Inhibitors Hirudin Lepirudin Bivalirudin Argatroban

5. Defibrinating Agents Ancrod